Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shenyan Kangfu Tablet
- Development stage
- Phase 4
- Lead developer
- Tianjin Tongrentang Group
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Shenyan Kangfu Tablet (SYKFT) is a Chinese patent medicine derived from traditional Chinese herbal formulations. It was originally designed for treating chronic nephritis patients diagnosed with qi-yin deficiency syndrome (characterized by lack of qi and yin energy in the body). SYKFT works primarily by inhibiting NF-κB signaling pathways to reduce renal inflammation and by modulating gut microbiota composition. Clinical evidence shows it can reduce blood glucose and HbA1c levels, alleviate renal dysfunction, and reduce glomerular and tubular damage in diabetic kidney disease.
- Brand names
- Shenyan Kangfu Tablet
- Other names
- Nephritis recovery tablets
02
Targets
NF-κB
Beyond the preview
Go deeper on Shenyan Kangfu Tablet.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shenyan Kangfu Tablet.